Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 14, 2006; 12(34): 5501-5508
Published online Sep 14, 2006. doi: 10.3748/wjg.v12.i34.5501
Table 1 Patient and treatment characteristics for the 7 patients with cervical and upper thoracic esophageal cancer
PatientNo.Tumordistancefrom UES (cm)StageInductionchemotherapyConcurrentchemotherapyXRT dose(GTV)XRT dose(CTV)XRT dose(supraclavical regions)
12T3N1M05-FU, CDDP64.8 Gy (2.31 Gy/f)50.4 Gy (1.8 Gy/f)50.4 Gy (1.8 Gy/f)
20T2N1M05-FU, paclitaxel59.9 Gy, (2.14 Gy/f)50.4 Gy (1.8 Gy/f)0
30T3N1M05-FU, CDDP64.8 Gy (1.8 Gy/f × 8, 2.21 Gy × 21)51.7 Gy (1.53 Gy/f × 8, 1.88 Gy × 21)46 Gy (1.36 Gy/f × 8, 1.67 Gy × 21)
46T3N0M05-FU, paclitaxel59.4 Gy (1.8 Gy/f)59.4 Gy (1.8 Gy/f)0
50T4N1M05-FU, CBP, docetaxel66 Gy (2.0 Gy/f)66 Gy (2.0 Gy/f)0
62.5T4N1M0CBP, paclitaxelCBP, paclitaxel66 Gy (2.0 Gy/f)56 Gy (1.7 Gy/f)56 Gy (1.7 Gy/f)
70T4N0M05-FU, CDDP66 Gy (2.0 Gy/f)60 Gy (1.8 Gy/f)60 Gy (1.8 Gy/f)